Major Recall: Over 67,000 Cases of Power Stick Deodorant Sold at Major Retailers

Over 67,000 cases of Power Stick deodorant sold at Dollar Tree, Walmart, and Amazon have been recalled due to manufacturing safety concerns. Consumers are advised to dispose of or return affected products.
On July 22, 2025, health authorities issued a recall for more than 67,000 cases of Power Stick deodorant, which were sold at popular retailers such as Dollar Tree, Walmart, and online via Amazon. The recall stems from an undisclosed manufacturing concern identified by the U.S. Food and Drug Administration (FDA), as the product did not meet federal safety standards.
The affected deodorants were produced by A.P. Deauville based in Easton, Pennsylvania. The FDA's investigation revealed that these products failed to fully comply with regulations designed to ensure safety, proper ingredient declaration, and correct strength. The specific nature of the compliance failure has not been detailed, nor has any associated risk level been assigned.
The recall includes several specific product lines:
- Power Stick for Her Roll-On Antiperspirant in Powder Fresh scent, 1.8 oz, with multiple affected lots.
- Power Stick Invisible Protection Roll-On in Spring Fresh, 1.8 oz, with listed affected lots.
- Power Stick Original Nourishing Invisible Protection Roll-On, 1.8 oz, with its respective lots.
Consumers who possess these deodorants are advised to dispose of the products safely or return them to the place of purchase to receive a refund. The recall is part of ongoing safety measures to protect consumers from potentially unsafe cosmetic products.
For more details, the FDA has published additional information regarding this recall. It is recommended that consumers stay informed about product safety alerts related to personal care items to avoid health risks.
Source: https://medicalxpress.com/news/2025-07-recalled-cases-deodorant-sold-dollar.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Texas Allocates $50 Million for Psychedelic Drug Research to Combat Addiction
Texas commits $50 million to research ibogaine, a promising psychedelic for addiction and brain injury treatment, supporting clinical trials and innovation in neurotherapy.
Innovative AI-Driven Development of Broad-Spectrum Coronavirus Antiviral Drugs
Harvard scientists utilize AI-enabled modeling to develop broad-spectrum antiviral drugs targeting coronaviruses, promising rapid and effective pandemic responses.
Assessing Hormone Therapy's Effects on Transgender Women's Athletic Performance
Explore recent research on how gender-affirming hormone therapy influences the athletic performance of transgender women, shedding light on physiological changes and performance outcomes in sports.
Major Challenges in Conducting Multinational Clinical Trials in Europe Uncovered
A new study uncovers significant ethical, regulatory, and logistical hurdles faced during European multinational clinical trials, highlighting the need for harmonized processes to accelerate research, especially during health crises.



